A Study of Vinblastine and Temsirolimus in Pediatric Patients with Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Temsirolimus (Primary) ; Vinblastine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Mar 2016 Planned End Date changed from 1 Feb 2019 to 1 May 2020 as per ClinicalTrials.gov record.
- 25 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.